Trial finds loberamisal improves 90-day outcomes after acute ischemic stroke

The LAIS phase 3 randomized trial evaluated intravenous loberamisal, a compound targeting the PSD-95 pathway and α2-GABAA receptor, added to standard care in patients with acute ischemic stroke treated within 48 hours of onset. The trial reported that 69.7% of patients receiving loberamisal achieved a modified Rankin Scale score of 0 to 1 at 90 days versus 56.3% with placebo, with similar rates of adverse events and serious adverse events between groups. The authors state further studies are needed to validate these findings and determine whether benefits extend to a broader patient population.

Most relevant for: Patients with acute ischemic stroke presenting within 48 hours of symptom onset with moderate stroke severity (NIHSS 7 to 20) and no prestroke disability.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.